- Home
- About us
- Products & Services
-
Wellworth Insurance
- Back Office
- Market Analysis
- Invest Options
- Corp Info
- Reports
| Senores Pharmaceuticals Ltd |
|---|
| Registered Office: #.1101-1103 11th Flr South Twr,Ambali Bopal Road,Ahmedabad-380054, Gujarat |
| Tel. No: +91-79-2999 9857 |
| Fax No: |
| Email: cs@senorespharma.com |
| Website: www.senorespharma.com |
| Initial public offering of 14,887,723 equity shares of face value of Rs. 10 each ("Equity Shares") of Senores Pharmaceuticals Limited ("The Company" or the "Issuer") for cash at a price of Rs. 391 per equity share (including a share premium of Rs. 381 per equity share) ("Offer Price") aggregating to Rs. 582.11 crores (the "Offer"). The offer comprises of a fresh issue of 12,787,723 equity shares by the company aggregating to Rs. 500.00 crores (the "Fresh Issue") and an offer for sale of 2,100,000 equity shares (the "Offered Shares") aggregating to Rs. 82.11 crores (the "Offer for Sale"), comprising 250,000 equity shares aggregating to Rs. 9.78 crores by Swapnil Jatinbhai Shah, 550,000 equity shares aggregating to Rs. 21.51 crores by Ashokkumar Vijaysinh Barot, 300,000 equity shares aggregating to Rs. 11.73 crores by Sangeeta Mukur Barot and 1,000,000 equity shares aggregating to Rs. 39.10 crores by Prakash M Sanghvi (the "Selling Shareholders"). The offer shall constitute 32.33 % of the post-offer paid-up equity share capital of the company. The offer includes a reservation of 75,000 equity shares, aggregating to Rs. 2.93 crores constituting 0.16% of the post-offer paid-up equity share capital, for subscription by eligible employees ("Employee Reservation Portion"). The offer less the employee reservation portion is hereinafter referred to as the "Net Offer". The face value of the equity shares is Rs. 10 each and the offer price is 39.10 times the face value of the equity shares. |
| Issue | Money Payable On | ||
|---|---|---|---|
| Opens On | Closes On | Application | Allotment |
| 20-Dec-2024 | 24-Dec-2024 | ₹391.00 - 0.00 | ₹0.00 - 0.00 |
| Minimum Application for shares in Nos : 38 | Further Multiples of : 38 |
|---|
| (₹ Cr) | Lead Managers to the Issue | |
|---|---|---|
| Project Cost | 457.81 | Ambit Pvt Ltd |
| Project Financed through Current Offer | 582.11 | Equirus Capital Pvt Ltd |
| Post Issue Equity Share Capital | 46.05 | Nuvama Wealth Management Ltd |
| Issue Price | 391.00 |
| Projects |
|---|
| Funding the capital expenditure requirements by investment in of one of your its subsidiary Havix,for setting up a mfg facility for the production of sterlie injection in its Atlanta Facility |
| Re-payment/pre-payment in full or in part of certain borrowings availed by the company and its subsidiary namely Havix Ratnatris and PSI |
| Funding the working capital requirements of the company and its subsidiary namely SPI ad Ratnatris |
| Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes |
| Investment in its subsidiary namely Havix for re-payment/pre-payment in full or in part of certain borrowings availd by the subsidiaries |
| Investment in its subsidiary namely SPI and Ratnatri to fund their working capital requirements |
| Promoted By |
|---|
| Swapnil Jatinbhai |
| Ashokkumar Vijaysingh Barot |
| Anar Swapnil Shah |
| Listing At |
|---|
| BSE |
| NSE |
| Registrar To The Issue | |
|---|---|
| Link Intime India Pvt Ltd |